reserpine has been researched along with Parkinson Disease in 151 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia." | 7.91 | Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019) |
| "Obesity is associated with low-grade chronic inflammation and oxidative stress, affecting the brain's reward system by decreasing dopaminergic neurotransmission." | 5.72 | Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease. ( Andrade, VM; Bitencourt, RM; Cavalheiro, EKFF; Cucker, L; da Silva, LE; Dal-Pizzol, F; Damiani, AP; Joaquim, L; Machado, RS; Magenis, ML; Michels, M; Oliveira, MP; Petronilho, F; Rezin, GT; Ribeiro, CB; Silva, MG; Tuon, T; Vilela, TC, 2022) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 5.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Present study was designed to monitor the cognitive profile of the animals upon repeated administration of reserpine, so as to determine that whether these animals should be used as animal models of Parkinson's dementia." | 3.91 | Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia. ( Haleem, DJ; Ikram, H, 2019) |
| " The aim of this study was to examine the influence of MK-801 on the reserpine-induced muscle rigidity." | 3.69 | Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. ( Lorenc-Koci, E; Ossowska, K; Wolfarth, S, 1994) |
| "The reserpine model was critical to the understanding of the role of monoamine system in the regulation of motor and affective disorders, as well as the efficacy of current PD treatments, such as L-DOPA and dopamine agonists." | 2.52 | Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model. ( Leão, AH; Ribeiro, AM; Santos, JR; Sarmento-Silva, AJ; Silva, RH, 2015) |
| "Tremor was assessed visually and with accelerometers." | 1.91 | Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model. ( Asan, E; Biella, GEM; Bolzoni, F; Cavallari, P; Ip, CW; Isaias, IU; Pezzoli, G; Pozzi, NG; Volkmann, J, 2023) |
| " This study evaluated the effect of chronic administration of testosterone propionate (TP) on motor behavior and neurochemical parameters in the reserpine-induced rat model of parkinsonism." | 1.72 | Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease. ( Bispo, JMM; Franco, HS; Gois, AM; Leal, PC; Lins, LCRF; Medeiros, KAAL; Melo, JEC; Ribeiro, AM; Santos, JR; Silva, RH; Silva, RS; Souza, MF, 2022) |
| "Obesity is associated with low-grade chronic inflammation and oxidative stress, affecting the brain's reward system by decreasing dopaminergic neurotransmission." | 1.72 | Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease. ( Andrade, VM; Bitencourt, RM; Cavalheiro, EKFF; Cucker, L; da Silva, LE; Dal-Pizzol, F; Damiani, AP; Joaquim, L; Machado, RS; Magenis, ML; Michels, M; Oliveira, MP; Petronilho, F; Rezin, GT; Ribeiro, CB; Silva, MG; Tuon, T; Vilela, TC, 2022) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 1.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Reserpine was toxic to worms (decreased the survival, food intake, development and changed egg laying and defecation cycles)." | 1.43 | Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans. ( Aschner, M; Caito, S; Chen, P; Fachinetto, R; Gubert, P; Reckziegel, P; Soares, FA, 2016) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain." | 1.34 | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. ( Brotchie, JM; Hallett, PJ, 2007) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| "Dopamine depletion in Parkinson's disease results in a series of pathophysiological changes in the basal ganglia circuitry." | 1.33 | Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. ( Dascombe, MJ; Ismayilova, N; Verkhratsky, A, 2006) |
| "Trihexyphenidyl (THP) is a drug commonly used to reduce parkinsonian symptoms." | 1.32 | Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats. ( Alvarez-Cervera, F; Arankowsky-Sandoval, G; Góngora-Alfaro, JL; Moo-Puc, RE; Villanueva-Toledo, J, 2004) |
| "Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11." | 1.31 | Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; McGuire, S; McInnes, A; Silverdale, MA, 2001) |
| "Before the use of L-Dopa, Parkinson's disease (PD) was considered a disabling disease with no effective treatment." | 1.31 | [Short history of L-Dopa]. ( García Ruiz, PJ; Meseguer, E, 2002) |
| "Reserpine was injected in a dose of 10 mg/kg alone or with alpha-methyl-p-tyrosine (250 mg/kg) 1, 4 and 27." | 1.29 | Does reserpine induce parkinsonian rigidity? ( Lorenc-Koci, E; Ossowska, K; Wardas, J; Wolfarth, S, 1995) |
| "In rodent models of Parkinson's disease such as reserpinized or 6-hydroxydopamine substantia nigra lesioned rats, blockade of glutamate receptors of the NMDA (N-methyl-D-aspartate) or the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptor subtypes and concomitant treatment with L-DOPA (L-3,4-dihydroxyphenylalanine) or direct dopamine agonists restores locomotor activity and induces rotations." | 1.29 | Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. ( Eblen, F; Kockgether, T; Löschmann, PA; Wachtel, H; Wüllner, U, 1995) |
| "When cabergoline was administered together with 3(3,4-dihydroxyphenyl)-L-alanine (L-DOPA), the effects were additive." | 1.29 | Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. ( Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F, 1996) |
| "Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract." | 1.28 | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. ( Cohen, G; Spina, MB, 1989) |
| "Pretreatment with haloperidol and sulpiride blocked the effects induced by ciladopa." | 1.27 | Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. ( Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ, 1986) |
| " Two lines of evidence strongly suggest that the bursting pallidal activities are a consequence of the interruption of the nigrostriatal dopaminergic pathway: (1) the percentage of bursting pallidal neurons is proportional to the amount of degeneration in the pars compacta of the ipsilateral substantia nigra; (2) chronic administration of dopamine antagonists, haloperidol and reserpine, reproduces in intact monkeys the bursting activities observed in lesioned animals." | 1.26 | Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. ( Filion, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 95 (62.91) | 18.7374 |
| 1990's | 14 (9.27) | 18.2507 |
| 2000's | 14 (9.27) | 29.6817 |
| 2010's | 16 (10.60) | 24.3611 |
| 2020's | 12 (7.95) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed-Farid, OA | 1 |
| Taha, M | 1 |
| Bakeer, RM | 1 |
| Radwan, OK | 1 |
| Hendawy, HAM | 1 |
| Soliman, AS | 1 |
| Yousef, E | 1 |
| Beserra-Filho, JIA | 1 |
| Maria-Macêdo, A | 1 |
| Silva-Martins, S | 1 |
| Custódio-Silva, AC | 1 |
| Soares-Silva, B | 1 |
| Silva, SP | 1 |
| Lambertucci, RH | 1 |
| de Souza Araújo, AA | 1 |
| Lucchese, AM | 1 |
| Quintans-Júnior, LJ | 1 |
| Santos, JR | 6 |
| Silva, RH | 7 |
| Ribeiro, AM | 7 |
| Bispo, JMM | 4 |
| Melo, JEC | 3 |
| Gois, AM | 4 |
| Medeiros, KAAL | 2 |
| Silva, RS | 1 |
| Leal, PC | 3 |
| Franco, HS | 2 |
| Souza, MF | 3 |
| Lins, LCRF | 4 |
| Cavalheiro, EKFF | 1 |
| da Silva, LE | 1 |
| Oliveira, MP | 1 |
| Silva, MG | 1 |
| Damiani, AP | 1 |
| Ribeiro, CB | 1 |
| Magenis, ML | 1 |
| Cucker, L | 1 |
| Michels, M | 1 |
| Joaquim, L | 1 |
| Machado, RS | 1 |
| Vilela, TC | 1 |
| Bitencourt, RM | 1 |
| Andrade, VM | 1 |
| Dal-Pizzol, F | 1 |
| Petronilho, F | 1 |
| Tuon, T | 1 |
| Rezin, GT | 1 |
| Santos, TFO | 1 |
| Santos, RS | 1 |
| Monteiro, MCN | 1 |
| Mendonça, MS | 1 |
| Marchioro, M | 3 |
| Marano, M | 1 |
| Tharwat, EK | 1 |
| Abdelaty, AO | 1 |
| Abdelrahman, AI | 1 |
| Elsaeed, H | 1 |
| Elgohary, A | 1 |
| El-Feky, AS | 1 |
| Ebrahim, YM | 1 |
| Sakraan, A | 1 |
| Ismail, HA | 1 |
| Khadrawy, YA | 1 |
| Aboul Ezz, HS | 1 |
| Noor, NA | 1 |
| Fahmy, HM | 1 |
| Mohammed, HS | 1 |
| Mohammed, FF | 1 |
| Radwan, NM | 1 |
| Ahmed, NA | 1 |
| da Cruz Guedes, E | 1 |
| Erustes, AG | 1 |
| Leão, AHFF | 1 |
| Carneiro, CA | 1 |
| Abílio, VC | 1 |
| Zuardi, AW | 1 |
| Hallak, JEC | 1 |
| Crippa, JA | 1 |
| Bincoletto, C | 1 |
| Smaili, SS | 1 |
| Reckziegel, P | 2 |
| Pereira, GJS | 1 |
| Oukhrib, M | 1 |
| Tamegart, L | 1 |
| Assafi, A | 1 |
| Hejji, L | 1 |
| Azzouz, A | 1 |
| Villarejo, LP | 1 |
| Haida, M | 1 |
| Mohamed, C | 1 |
| Gamrani, H | 2 |
| Pozzi, NG | 1 |
| Bolzoni, F | 1 |
| Biella, GEM | 1 |
| Pezzoli, G | 1 |
| Ip, CW | 1 |
| Volkmann, J | 1 |
| Cavallari, P | 1 |
| Asan, E | 1 |
| Isaias, IU | 1 |
| Pereira, AG | 1 |
| Poli, A | 1 |
| Matheus, FC | 1 |
| de Bortoli da Silva, L | 1 |
| Fadanni, GP | 1 |
| Izídio, GS | 1 |
| Latini, A | 1 |
| Prediger, RD | 1 |
| Jampolska, M | 1 |
| Andrzejewski, K | 1 |
| Zaremba, M | 1 |
| Joniec-Maciejak, I | 1 |
| Kaczyńska, K | 1 |
| Luo, Y | 1 |
| Li, Z | 1 |
| Peng, X | 1 |
| Xia, L | 1 |
| Ma, L | 1 |
| Moore, C | 1 |
| Meshul, CK | 1 |
| Ikram, H | 1 |
| Haleem, DJ | 1 |
| Draoui, A | 1 |
| El Hiba, O | 1 |
| Abdelaati, EK | 1 |
| Abbaoui, A | 1 |
| El Fari, R | 1 |
| Aitihya, M | 1 |
| El-Ghazaly, MA | 1 |
| Sadik, NA | 1 |
| Rashed, ER | 1 |
| Abd-El-Fattah, AA | 1 |
| Chen, P | 1 |
| Caito, S | 1 |
| Gubert, P | 1 |
| Soares, FA | 1 |
| Fachinetto, R | 1 |
| Aschner, M | 1 |
| Leão, AH | 1 |
| Sarmento-Silva, AJ | 1 |
| Devadasan, C | 1 |
| Starr, B | 1 |
| Doyle, KM | 1 |
| Fernandes, VS | 1 |
| Melo, TG | 1 |
| Godinho, M | 1 |
| Barbosa, FF | 1 |
| Medeiros, DS | 1 |
| Munguba, H | 1 |
| Ghosh, B | 1 |
| Antonio, T | 1 |
| Zhen, J | 1 |
| Kharkar, P | 1 |
| Reith, ME | 1 |
| Dutta, AK | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Villar-Cheda, B | 1 |
| Rodríguez-Pallares, J | 1 |
| Valenzuela, R | 1 |
| Muñoz, A | 1 |
| Guerra, MJ | 1 |
| Baltatu, OC | 1 |
| Labandeira-Garcia, JL | 1 |
| Tozzi, A | 1 |
| de Iure, A | 1 |
| Di Filippo, M | 1 |
| Tantucci, M | 1 |
| Costa, C | 1 |
| Borsini, F | 1 |
| Ghiglieri, V | 1 |
| Giampà, C | 1 |
| Fusco, FR | 1 |
| Picconi, B | 1 |
| Calabresi, P | 1 |
| Broadstock, M | 1 |
| Austin, PJ | 1 |
| Betts, MJ | 1 |
| Duty, S | 2 |
| Lima, MM | 1 |
| Andersen, ML | 1 |
| Reksidler, AB | 1 |
| Ferraz, AC | 1 |
| Vital, MA | 2 |
| Tufik, S | 1 |
| Muñoz, P | 1 |
| Paris, I | 1 |
| Sanders, LH | 1 |
| Greenamyre, JT | 1 |
| Segura-Aguilar, J | 1 |
| Skalisz, LL | 1 |
| Beijamini, V | 1 |
| Joca, SL | 1 |
| Da Cunha, C | 1 |
| Andreatini, R | 1 |
| Segovia, G | 1 |
| Mora, F | 1 |
| Crossman, AR | 3 |
| Brotchie, JM | 5 |
| Valenti, O | 1 |
| Marino, MJ | 1 |
| Wittmann, M | 1 |
| Lis, E | 1 |
| DiLella, AG | 1 |
| Kinney, GG | 1 |
| Conn, PJ | 1 |
| BENTE, D | 1 |
| ITIL, T | 1 |
| HAASE, HJ | 2 |
| BUTTON, JC | 1 |
| MAY, RH | 1 |
| VOEGELE, GE | 1 |
| RASHKIS, HA | 1 |
| SMARR, ER | 1 |
| FREYHAN, FA | 2 |
| GIBERTI, F | 1 |
| GIANNIOTTI, G | 1 |
| SPIZZIRRI, S | 1 |
| BAYREUTHER, H | 1 |
| HASKOVEC, L | 1 |
| KNAUF, HW | 1 |
| CAHAN, RB | 1 |
| PARRISH, DD | 1 |
| GUGGENHEIM, P | 1 |
| COHEN, L | 1 |
| GOLDSCHMIDT, D | 1 |
| BROSCH, H | 1 |
| MARKHAM, CH | 1 |
| CLARK, WG | 1 |
| WINTERS, WD | 1 |
| BIRKMAYER, W | 2 |
| HORNYKIEWICZ, O | 3 |
| Nakao, N | 1 |
| Shintani-Mizushima, A | 1 |
| Kakishita, K | 1 |
| Itakura, T | 1 |
| Moo-Puc, RE | 1 |
| Villanueva-Toledo, J | 1 |
| Arankowsky-Sandoval, G | 1 |
| Alvarez-Cervera, F | 1 |
| Góngora-Alfaro, JL | 1 |
| Johnston, TH | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Fox, SH | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Ismayilova, N | 1 |
| Verkhratsky, A | 1 |
| Dascombe, MJ | 1 |
| Hallett, PJ | 1 |
| Kreitzer, AC | 1 |
| Malenka, RC | 1 |
| Abbott, A | 1 |
| Gershanik, O | 1 |
| Heikkila, RE | 1 |
| Duvoisin, RC | 4 |
| Diamond, BI | 2 |
| Pasinetti, G | 1 |
| Hitri, A | 1 |
| Borison, RL | 2 |
| Cooper, DR | 2 |
| Marrel, C | 2 |
| Testa, B | 2 |
| van de Waterbeemd, H | 2 |
| Quinn, N | 1 |
| Jenner, P | 4 |
| Marsden, CD | 5 |
| Atadzhanov, M | 1 |
| Fahn, S | 2 |
| Kehr, W | 1 |
| Loeffler, DA | 1 |
| LeWitt, PA | 1 |
| DeMaggio, AJ | 1 |
| Juneau, PL | 1 |
| Milbury, PE | 1 |
| Matson, WR | 1 |
| Ossowska, K | 3 |
| Lorenc-Koci, E | 3 |
| Wolfarth, S | 3 |
| Wardas, J | 1 |
| Löschmann, PA | 1 |
| Eblen, F | 1 |
| Wüllner, U | 1 |
| Wachtel, H | 1 |
| Kockgether, T | 1 |
| Maneuf, YP | 1 |
| Hille, CJ | 1 |
| Drukarch, B | 1 |
| Jongenelen, CA | 1 |
| Schepens, E | 1 |
| Langeveld, CH | 1 |
| Stoof, JC | 1 |
| Brooks, S | 1 |
| Kaur, S | 1 |
| Starr, BS | 1 |
| Starr, MS | 1 |
| Miyagi, M | 1 |
| Arai, N | 1 |
| Taya, F | 1 |
| Itoh, F | 1 |
| Komatsu, Y | 1 |
| Kojima, M | 1 |
| Isaji, M | 1 |
| Menzaghi, F | 1 |
| Whelan, KT | 1 |
| Risbrough, VB | 1 |
| Rao, TS | 1 |
| Lloyd, GK | 1 |
| Konieczny, J | 1 |
| Tolwani, RJ | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Sikiric, P | 1 |
| Marovic, A | 1 |
| Matoz, W | 1 |
| Anic, T | 1 |
| Buljat, G | 1 |
| Mikus, D | 1 |
| Stancic-Rokotov, D | 1 |
| Separovic, J | 1 |
| Seiwerth, S | 1 |
| Grabarevic, Z | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Ziger, T | 1 |
| Sebecic, B | 1 |
| Zoricic, I | 1 |
| Turkovic, B | 1 |
| Aralica, G | 1 |
| Perovic, D | 1 |
| Duplancic, B | 1 |
| Lovric-Bencic, M | 1 |
| Rotkvic, I | 1 |
| Mise, S | 1 |
| Jagic, V | 1 |
| Hahn, V | 1 |
| Silverdale, MA | 1 |
| McGuire, S | 1 |
| McInnes, A | 1 |
| García Ruiz, PJ | 1 |
| Meseguer, E | 1 |
| Hebenstreit, G | 1 |
| Filion, M | 1 |
| Hassler, R | 2 |
| Wagner, A | 1 |
| Pletscher, A | 2 |
| Raheem, KA | 1 |
| Gründig, E | 1 |
| Salvenmoser, F | 1 |
| Schedl, R | 1 |
| Weiss, J | 1 |
| Clemens, R | 1 |
| David, J | 1 |
| Kaul, CL | 1 |
| Grewal, RS | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Parkes, JD | 1 |
| Pycock, C | 2 |
| Tarsy, D | 2 |
| Dolphin, A | 1 |
| Stimmel, GL | 1 |
| Sofic, E | 1 |
| Lange, KW | 1 |
| Jellinger, K | 1 |
| Riederer, P | 1 |
| Klockgether, T | 1 |
| Turski, L | 1 |
| Jankovic, J | 1 |
| Casabona, J | 1 |
| Spina, MB | 1 |
| Cohen, G | 1 |
| de Yebenes, JG | 1 |
| Jackson-Lewis, V | 1 |
| Jorge, P | 1 |
| Mena, MA | 1 |
| Reiriz, J | 1 |
| Koller, WC | 1 |
| Fields, JZ | 1 |
| Gordon, JH | 1 |
| Perlow, MJ | 1 |
| Hinzen, D | 1 |
| Kobinger, W | 1 |
| Pichler, L | 1 |
| Pifl, C | 1 |
| Schingnitz, G | 1 |
| Martin, WE | 1 |
| Villeneuve, A | 1 |
| Böszörményi, Z | 1 |
| Godtfredsen, E | 1 |
| Poirier, LJ | 2 |
| Langelier, P | 1 |
| Bédard, P | 2 |
| Boucher, R | 1 |
| Larochelle, L | 2 |
| Parent, A | 2 |
| Roberge, AG | 1 |
| Steg, G | 2 |
| Curzon, G | 1 |
| Jurna, I | 1 |
| Stern, J | 1 |
| Mendell, J | 1 |
| Clark, K | 1 |
| Müller-Calgan, H | 1 |
| Sommer, S | 1 |
| Hartmann-von Monakow, K | 1 |
| Chase, TN | 1 |
| Nelson, SR | 1 |
| Walaszek, EJ | 1 |
| Roos, BE | 2 |
| Carlsson, A | 2 |
| Van Loon, GR | 1 |
| Hinterbuchner, LP | 1 |
| Hinterbuchner, C | 1 |
| Turunen, S | 1 |
| Achté, KA | 1 |
| Klawans, HL | 1 |
| Gordon, N | 1 |
| Sourkes, TL | 1 |
| Brossi, A | 1 |
| Pool, W | 1 |
| Sheppard, H | 1 |
| Burns, JJ | 1 |
| Kaiser, A | 1 |
| Bigler, R | 1 |
| Bartholini, G | 2 |
| Vogt, M | 1 |
| Borgman, RJ | 1 |
| Mcphillips, JJ | 1 |
| Stitzel, RE | 1 |
| Goodman, IJ | 1 |
| Thody, AJ | 1 |
| Shuster, S | 1 |
| Tret'iakova, KA | 1 |
| Samoĭlova, ZT | 1 |
| Morrison, AB | 1 |
| Webster, RA | 1 |
| Ganev, G | 1 |
| Karamalakov, L | 1 |
| Milenkov, K | 1 |
| Ianachkova, M | 1 |
| Sakhatchieva, L | 1 |
| Kiuchukova, P | 1 |
| Roĭlev, I | 1 |
| Naumov, I | 1 |
| Cheshmedzhiev, P | 1 |
| Dochkov, Zh | 1 |
| Degkwitz, R | 2 |
| Sano, Y | 1 |
| Murase, Y | 1 |
| Mones, RJ | 1 |
| Goodwin, FK | 1 |
| Murphy, DL | 1 |
| Brodie, HK | 1 |
| Bunney, WE | 1 |
| Kaeser, HE | 1 |
| Ferel, D | 1 |
| Wurmser, P | 1 |
| Sutherland, JM | 1 |
| Castaigne, P | 1 |
| Rondot, P | 1 |
| Ribadeau-Dumas, JL | 1 |
| North, RR | 1 |
| Pozos, RS | 1 |
| Holbrook, JR | 1 |
| Farnebo, LO | 1 |
| Fuxe, K | 1 |
| Goldstein, M | 1 |
| Hamberger, B | 1 |
| Ungerstedt, U | 1 |
| Ericsson, AD | 1 |
| Wertman, BG | 1 |
| Blum, B | 1 |
| Weizmann, H | 1 |
| Simpson, GM | 1 |
| Krasilowsky, D | 1 |
| Kulcsar, IS | 1 |
| Merskey, H | 1 |
| Story, JL | 1 |
| French, LA | 1 |
| Chou, SN | 1 |
| Meier, MJ | 1 |
| Tissot, R | 1 |
| Radouco-Thomas, S | 1 |
| Hornykiewicz, OD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease[NCT02324426] | Phase 1 | 15 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Phase IIb Study of Intranasal Glutathione in Parkinson's Disease[NCT02424708] | Phase 2 | 45 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for reserpine and Parkinson Disease
| Article | Year |
|---|---|
Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Humans; Mental Disorders; Parkinson Di | 2015 |
[Modeling parkinsonism (review)].
Topics: Aluminum; Animals; Carbachol; Cats; Caudate Nucleus; Chlorides; Chlorpromazine; Disease Models, Anim | 1982 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
[The use of psychotropic drugs in general practice].
Topics: Alcohol Withdrawal Delirium; Anti-Anxiety Agents; Anxiety; Benzhydryl Compounds; Benzodiazepines; Bi | 1977 |
Locomotor activity and speed of movements in relation to monoamine-acting drugs.
Topics: Animals; Atropine; Basal Ganglia; Cats; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Harmalin | 1975 |
Platelets as models for monoaminergic neurons.
Topics: Affective Symptoms; Animals; Biogenic Amines; Blood Platelets; Catecholamines; Cell Membrane; Child; | 1978 |
The biochemistry of dyskinesias.
Topics: Acetylcholine; Animals; Catecholamines; Cats; Copper; Dihydroxyphenylalanine; Dogs; Hepatolenticular | 1967 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
Pharmacology of the central nervous system.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Adrenocorticotropic Hormone; Amphetamine; Anger; Angiote | 1968 |
Biochemical and pharmacological aspects of Parkinsonism.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Chemoreceptor Cells; Chlorpromazine; Co | 1972 |
The role of brain catecholamines in the regulation of ACTH secretion.
Topics: 17-Hydroxycorticosteroids; Acetylcholine; Adrenal Cortex Hormones; Adrenal Glands; Adrenalectomy; Ad | 1974 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanin | 1972 |
Functional aspects of the role of catecholamines in the central nervous system.
Topics: Animals; Brain; Catecholamines; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Epinephrine; Huma | 1973 |
[l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
Topics: Acetylcholine; Basal Ganglia; Butyrophenones; Chorea; Dihydroxyphenylalanine; Dopamine; Extrapyramid | 1969 |
[Biochemistry of the extrapyramidal system--from anatomical viewpoint].
Topics: Amines; Animals; Cytoplasm; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Histocytochemis | 1968 |
Parkinson's disease. II.
Topics: Basal Ganglia; Catecholamines; Dihydroxyphenylalanine; Gait; Humans; Mental Processes; Movement Diso | 1970 |
L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Topics: Aged; Aggression; Anger; Behavior; Bipolar Disorder; Brain; Brain Chemistry; Carboxy-Lyases; Catecho | 1970 |
Parkinson's syndrome: aetiological factors and certain clinical features.
Topics: Adult; Aged; Brain Injuries; Butyrophenones; Female; Humans; Intracranial Arteriosclerosis; Male; Me | 1971 |
5 trials available for reserpine and Parkinson Disease
| Article | Year |
|---|---|
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla | 2004 |
Treatment of drug-induced dyskinesias.
Topics: Aged; Dihydroxyphenylalanine; Humans; Methyldopa; Middle Aged; Movement Disorders; Parkinson Disease | 1970 |
[Prophylaxis of neuroleptic parkonsonism with the Bulgarian drug INKhA-17 (Paabainkh) and bellazon].
Topics: Bulgaria; Chlorpromazine; Clinical Trials as Topic; Humans; Isoniazid; Mental Disorders; Parasympath | 1968 |
L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
Topics: Aged; Aggression; Anger; Behavior; Bipolar Disorder; Brain; Brain Chemistry; Carboxy-Lyases; Catecho | 1970 |
Harmine antagonism of drug-induced extra-pyramidal disturbances.
Topics: Alkaloids; Anticonvulsants; Chlorpromazine; Clinical Trials as Topic; Encephalitis; Female; Humans; | 1964 |
128 other studies available for reserpine and Parkinson Disease
| Article | Year |
|---|---|
Effects of bee venom and dopamine-loaded nanoparticles on reserpine-induced Parkinson's disease rat model.
Topics: Animals; Antiparkinson Agents; Bee Venoms; Brain-Derived Neurotrophic Factor; DNA Fragmentation; Dop | 2021 |
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism.
Topics: alpha-Synuclein; Animals; Antioxidants; beta-Cyclodextrins; Disease Models, Animal; Dopaminergic Neu | 2022 |
Testosterone propionate improves motor alterations and dopaminergic damage in the reserpine-induced progressive model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Female; Humans; Male; Motor Activity; Parkinson Disease; | 2022 |
Effects of obesity on neuroinflammatory and neurochemical parameters in an animal model of reserpine-induced Parkinson's disease.
Topics: Animals; Disease Models, Animal; Inflammation; Obesity; Oxidative Stress; Parkinson Disease; Reserpi | 2022 |
Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Topics: Aging; Animals; Catalepsy; Disease Models, Animal; Dopamine; Male; Motor Activity; Motor Disorders; | 2022 |
Reserpine induced parkinsonism, a hidden threat of herbal medicine.
Topics: Humans; Parkinson Disease; Parkinsonian Disorders; Plant Extracts; Plants, Medicinal; Reserpine | 2023 |
Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Topics: Acetylcholinesterase; Animals; Disease Models, Animal; Lithium; Male; Neurodegenerative Diseases; Pa | 2023 |
Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.
Topics: Aged; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditi | 2023 |
Effects of graphene oxide nanoparticles administration against reserpine-induced neurobehavioral damage and oxidative stress in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative D | 2023 |
Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model.
Topics: Animals; Brain; Humans; Male; Norepinephrine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpi | 2023 |
Temporal development of neurochemical and cognitive impairments following reserpine administration in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum; Dis | 2020 |
Deficiency of Biogenic Amines Modulates the Activity of Hypoglossal Nerve in the Reserpine Model of Parkinson's Disease.
Topics: Animals; Biogenic Amines; Disease Models, Animal; Humans; Hypoglossal Nerve; Male; Parkinson Disease | 2021 |
Desipramine rescues emotional memory deficit induced by low doses of reserpine.
Topics: Amygdala; Animals; Cues; Desipramine; Emotions; Fear; Long-Term Potentiation; Male; Memory; Memory D | 2017 |
Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.
Topics: Animals; Anxiety; Brain; CA1 Region, Hippocampal; Cognition; Corpus Striatum; Disease Models, Animal | 2019 |
Sex differences in the progressive model of parkinsonism induced by reserpine in rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Male; Motor Ac | 2019 |
Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's dementia.
Topics: Animals; Brain; Dementia; Disease Models, Animal; Dopamine; Hydroxyindoleacetic Acid; Male; Memory; | 2019 |
Differential impairment of short working and spatial memories in a rat model of progressive Parkinson's disease onset: A focus on the prodromal stage.
Topics: Amygdala; Animals; Astrocytes; Brain; Disease Models, Animal; Hippocampus; Male; Memory Disorders; M | 2019 |
Neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apoptosis; Behavior, Animal; Brain Chemistry; Catalepsy; Combined Mod | 2015 |
Extracellular dopamine and alterations on dopamine transporter are related to reserpine toxicity in Caenorhabditis elegans.
Topics: Animals; Animals, Genetically Modified; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Def | 2016 |
Effect of N1-dansylspermine and Ro25,6981 on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Dansyl Compounds; Disease Models, Animal; Dose- | 2016 |
Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson disease.
Topics: Animals; Antipsychotic Agents; Data Interpretation, Statistical; Emotions; Fear; Male; Memory Disord | 2008 |
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; CHO Cells; Cricetinae; Cricetulus; Disease Models, An | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Angiotensin II; Animals; Corpus Striatum; Disease Progression; Dopamin | 2010 |
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Cells, Cultured; Cholinergic Agents; Corpus Striatum; Dendrit | 2011 |
Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitator | 2012 |
Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.
Topics: alpha-Methyltyrosine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulati | 2012 |
Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.
Topics: Analysis of Variance; Animals; Cell Death; Cell Line; DNA; Dopamine; Humans; Indolequinones; Lobelin | 2012 |
Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Food Preferences; Injections, Intrape | 2002 |
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Cannabinoid Receptor | 2003 |
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse.
Topics: Adrenergic Uptake Inhibitors; Aminobutyrates; Animals; Corpus Striatum; Disease Models, Animal; Elec | 2003 |
[The effects of high-dosed reserpin (serpasil) treatment and drug-induced parkinsonism-like states on the electroencephalogram].
Topics: Antihypertensive Agents; Chlorpromazine; Electroencephalography; Humans; Parkinson Disease; Parkinso | 1955 |
[Psychiatric experiences with megaphen (largactil) and the Rauwolfia alkaloid serpasil with special reference to Parkinson's psychomotor syndrome].
Topics: Antihypertensive Agents; Chlorpromazine; Parkinson Disease; Rauwolfia; Reserpine; Schizophrenia; Sec | 1955 |
Meratran with reserpine; adjunctive use in the treatment of Parkinson's disease.
Topics: Antihypertensive Agents; Central Nervous System Stimulants; Humans; Parkinson Disease; Reserpine; Se | 1956 |
Parkinsonian reactions following chlorpromazine and reserpine; similar reactions in the same patients.
Topics: Antihypertensive Agents; Chlorpromazine; Parkinson Disease; Reserpine; Secologanin Tryptamine Alkalo | 1956 |
[Definition and mode of action of the psychomotor Parkinson syndrome therapeutically induced by serpasil and largactil].
Topics: Antihypertensive Agents; Chlorpromazine; Parkinson Disease; Reserpine; Secologanin Tryptamine Alkalo | 1956 |
Protection against reserpine-induced Parkinsonism.
Topics: Humans; Parkinson Disease; Parkinsonian Disorders; Reserpine; Trihexyphenidyl | 1957 |
Psychomotility and parkinsonism in treatment with neuroleptic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Electroconvulsive Therapy; Humans; Mental Disorders; Movement; | 1957 |
[Further results of new therapy of Parkinsonian syndromes; therapeutic action of 3-phenyl-3-b-diethylamino-ethyl-2-6-dioxy-piperidine hydrochloride administered alone and with reserpine and ritalin].
Topics: Methylphenidate; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpi | 1957 |
[Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies; chlorpromazine, reserpine and prochlorperazine].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans | 1957 |
[The significance of reserpine-induced parkinsonism for the treatment of schizophrenia].
Topics: Parkinson Disease; Parkinsonian Disorders; Reserpine; Schizophrenia | 1958 |
[Contribution to the parkinsonian effects of chlorpromazine & reserpine].
Topics: Chlorpromazine; Humans; Parkinson Disease; Reserpine | 1958 |
[Treatment of parkinsonism-like syndromes caused by reserpine & chlorpromazine].
Topics: Chlorpromazine; Humans; Parkinson Disease; Parkinsonian Disorders; Piperidines; Reserpine; Syndrome | 1958 |
Investigations into the so-called reserpine Parkinsonoid in chronic schizophrenics and its treatment with orphenadrine (disipal).
Topics: Anticonvulsants; Humans; Orphenadrine; Parkinson Disease; Reserpine; Schizophrenia | 1959 |
Reversibility of drug-induced parkinsonism.
Topics: Chlorpromazine; Parkinson Disease; Parkinsonian Disorders; Reserpine | 1960 |
Theoretical considerations in parkinsonism induced by tranquilizing drugs.
Topics: Chlorpromazine; Parkinson Disease; Parkinsonian Disorders; Reserpine; Tranquilizing Agents | 1959 |
[Experiences and conclusions in regard to the use of hirepin. Part I].
Topics: Chlorpromazine; Parkinson Disease; Perphenazine; Reserpine | 1960 |
[Report on the use of Akineton in reserpineinduced Parkinsonoid states].
Topics: Biperiden; Parasympatholytics; Parkinson Disease; Reserpine | 1963 |
EFFECT OF ALPHA-METHYL DOPA AND RESERPINE IN HUNTINGTON'S CHOREA, PARKINSON'S DISEASE AND OTHER MOVEMENT DISORDERS.
Topics: Adolescent; Chorea; Dystonia Musculorum Deformans; Dystonic Disorders; Genetic Diseases, X-Linked; H | 1963 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson | 1964 |
Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Diseas | 2004 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats.
Topics: Animals; Basal Ganglia; Binding Sites; Male; Motor Activity; Parkinson Disease; Pyridines; Rats; Rat | 2006 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2007 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |
Neuroscience: the molecular wake-up call.
Topics: Animals; Dopamine; Europe; History, 20th Century; History, 21st Century; Humans; Maryland; Movement; | 2007 |
Behavioral correlations of dopamine receptor activation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1983 |
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain; Cholecystokinin; Dopamine; Drug Interactions; Extrapyramidal T | 1984 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 1984 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis.
Topics: Animals; Dizocilpine Maleate; Foot; Male; Muscle Rigidity; Muscle Tonus; Parkinson Disease; Rats; Ra | 1994 |
Does reserpine induce parkinsonian rigidity?
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Electromyography; Enzyme Inhibitors; Hi | 1995 |
Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Lamotrigine; Male; Mot | 1995 |
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzopyrans; Cromakalim; Diazoxide; Disease Mode | 1996 |
Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Buthionine Sulfoximine; Cytoplasmic Granules; Dopamine; Glutathione; | 1996 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Mono | 1996 |
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson | 1996 |
Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Corpus Striatum; Dextroamphetamine; Dopamine; Ion Channel | 1997 |
The role of striatal glutamate receptors in models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory | 1998 |
A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.
Topics: Animals; Anti-Ulcer Agents; Behavior, Animal; Body Temperature; Catalepsy; Hypothermia; Male; Mice; | 1999 |
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Cannabinoid Receptor Modulators; Cannabinoids; Cerebral Cortex; Corpus Str | 2001 |
[Short history of L-Dopa].
Topics: Antiparkinson Agents; Antipsychotic Agents; History, 20th Century; Humans; Levodopa; Parkinson Disea | 2002 |
Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey.
Topics: Animals; Apomorphine; Corpus Striatum; Evoked Potentials; Globus Pallidus; Haloperidol; Haplorhini; | 1979 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines | 1978 |
Incorporation of [U-14 C]glucose into metabolites of brain, liver and blood of rats pretreated with reserpine or phenothiazines.
Topics: Amino Acids; Animals; Blood Glucose; Brain; Glucose; Glycogen; Lipid Metabolism; Liver; Liver Glycog | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physica | 1976 |
Parkinsonism: animal analogues of the human disorder.
Topics: Animals; Butyrophenones; Chlorpromazine; Disease Models, Animal; Haplorhini; Hydroxydopamines; Levod | 1976 |
Effect of intracaudate drug injections on the striatal syndrome in reserpinized cats.
Topics: Animals; Apomorphine; Atropine; Cats; Caudate Nucleus; Corpus Striatum; Dextroamphetamine; Disease M | 1977 |
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
Topics: Amantadine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Dopamine; Extrapyram | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Diseas | 1975 |
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.
Topics: Animals; Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Humans; Male; Met | 1975 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Electrochemistry; Female; Free Radica | 1992 |
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Electrochemistry; Female; Free Radica | 1992 |
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Electrochemistry; Female; Free Radica | 1992 |
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Electrochemistry; Female; Free Radica | 1992 |
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Mot | 1990 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; M | 1987 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levo | 1987 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione | 1989 |
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain Diseases; Catheterization; Cerebral Ventricles; Disease Models, | 1988 |
Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Body Temperature; Dogs; Dose-Response Relationship, Drug | 1986 |
The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.
Topics: Animals; Azepines; Brain Chemistry; Drug Interactions; Ibotenic Acid; Macaca mulatta; Male; Mice; Mi | 1986 |
Tyrosine hydroxylase deficiency. A unifying concept of Parkinsonism.
Topics: Age Factors; Dihydroxyphenylalanine; Dopamine; Dopamine Antagonists; Humans; Mixed Function Oxygenas | 1971 |
Enzyme blocking in neuro-ophthalmology as tools and diseases.
Topics: Amino Acid Metabolism, Inborn Errors; Enzyme Inhibitors; Humans; Monoamine Oxidase Inhibitors; Parki | 1972 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
Alpha-rigidity in reserpinized rats.
Topics: Animals; Dihydroxyphenylalanine; Electromyography; Electrophysiology; Movement Disorders; Muscle Spi | 1964 |
[Experimental findings and new aspects in extrapyramidal diseases].
Topics: 5-Hydroxytryptophan; Blood Pressure; Body Temperature Regulation; Chorea; Dihydroxyphenylalanine; Do | 1966 |
Reserpine rigidity in the rat--a model for the analysis of antiparkinson drugs.
Topics: 1-Propanol; Animals; Biperiden; Cerebral Decortication; Electromyography; Methamphetamine; Models, N | 1968 |
H reflex suppression by thalamic stimulation and drug administration.
Topics: Chlorpromazine; Diazepam; Electric Stimulation; Humans; Motor Neurons; Muscle Spindles; Oscillometry | 1968 |
[Reserpine-parkinsonoid syndrome in the chimpanzee and its treatment with fencamfamin].
Topics: Animals; Antidepressive Agents; Catatonia; Hominidae; Humans; Movement Disorders; Parkinson Disease; | 1968 |
[Specific therapy of extrapyramidal-motor syndromes].
Topics: Analgesics; Athetosis; Chorea; Datura stramonium; Dihydroxyphenylalanine; Dystonia Musculorum Deform | 1969 |
[Parkinson's syndrome. 10. Effects of psychopharmacological agents on central monoamine neurons].
Topics: Amitriptyline; Humans; Imipramine; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Reserpi | 1970 |
Basic concepts underlying recent developments in the field of Parkinson's disease.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Humans; Parkinson Disease; P | 1971 |
[Correlations between chemical mediators (dopamine, serotonin, acetylcholine and gaba), muscular tone and rapidity of movement].
Topics: 5-Hydroxytryptophan; Acetylcholine; Alkaloids; Aminobutyrates; Animals; Dihydroxyphenylalanine; Dopa | 1972 |
Exaggerated response to levodopa. A case of "contaminated parkinsonism".
Topics: Aged; Drug Synergism; Humans; Levodopa; Male; Parkinson Disease; Reserpine | 1974 |
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
Topics: Adult; Aged; Brain Damage, Chronic; Cheek; Chlorpromazine; Chlorprothixene; Clopenthixol; Female; Ha | 1967 |
Drugs and motor functions.
Topics: Athetosis; Catecholamines; Cholinesterase Inhibitors; Chorea; Dihydroxyphenylalanine; Dopamine; Extr | 1971 |
Actions of levodopa and dopamine in the central nervous system.
Topics: Animals; Apomorphine; Binding Sites; Brain; Central Nervous System; Chlorpromazine; Dihydroxyphenyla | 1971 |
[Control of motor activity in relation to monoaminergic mechanisms].
Topics: Animals; Brain; Catatonia; Cerebellum; Corpus Striatum; Dopamine; Dopamine Antagonists; Haplorhini; | 1972 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermi | 1974 |
Synthesis and pharmacology of centrally acting dopamine derivatives qnd analogs in relation to parkinson's disease.
Topics: Acetylation; Alkylation; Animals; Body Temperature; Chemical Phenomena; Chemistry; Dopamine; Hydroly | 1973 |
The control of melanocyte-stimulating hormone secretion.
Topics: Animals; Brain; Catecholamines; Chlorpromazine; Dihydroxyphenylalanine; Humans; Hypothalamus; Inject | 1973 |
[The reserpine model of parkinsonism and changes in the metabolism of mediators].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Epinephrine; Male; Norepin | 1973 |
Drug-induced experimental Parkinsonism.
Topics: Animals; Atropine; Benztropine; Butyrophenones; Cats; Chlorpromazine; Dose-Response Relationship, Dr | 1973 |
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
Topics: Animals; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Dose | 1974 |
[Treatment of Parkinson's syndrome with L-dopa].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Antihypertensive Agents; Barbiturates; | 1970 |
[Drug-induced Parkinson's syndrome].
Topics: Acetylcholinesterase; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Movement Disor | 1972 |
[Medical treatment of Parkinson's disease].
Topics: Amantadine; Carboxy-Lyases; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease; P | 1972 |
Drug-induced movement disorders.
Topics: Amphetamine; Contraceptives, Oral; Dihydroxyphenylalanine; Dystonia Musculorum Deformans; Female; Hu | 1971 |
Tremorogenisis: effects of reserpine on the substantia nigra.
Topics: Animals; Cell Nucleus; Computers; Cytoplasmic Granules; Dogs; Electromyography; Forelimb; Hand; Huma | 1971 |
Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.
Topics: Amantadine; Animals; Catecholamines; Central Nervous System; Dopamine; Electrocoagulation; Hindlimb; | 1971 |
Sensitivity studies of L-dopa metabolites in reserpinized rats and their clinical significance.
Topics: Animals; Brain; Catechols; Dihydroxyphenylalanine; Female; Humans; Male; Mandelic Acids; Middle Aged | 1971 |
The effect of drugs inducing Parkinson's syndrome on muscle reflex mechanisms. A summary.
Topics: Animals; Chlorpromazine; Electrophysiology; Motor Neurons; Muscles; Parkinson Disease; Phenoxybenzam | 1965 |
Experiences with subthalamic lesions in patients with movement disorders.
Topics: Animals; Diencephalon; Humans; Parkinson Disease; Reserpine; Stereotaxic Techniques; Thalamus | 1965 |
[Pharmaco-biochemical mechanisms and modern therapy in Parkinsonian syndromes].
Topics: Animals; Central Nervous System; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tr | 1970 |
[Extrapyramidal syndrome in animal experiments: rôle of calcium and o-methylated derivatives].
Topics: Animals; Calcium; Calcium Metabolism Disorders; Depression, Chemical; Dihydroxyphenylalanine; Dopami | 1970 |
Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Injections, Intraperitoneal; Injections, I | 1970 |